Table 3.

AEs occurring in ≥10% of subjects

(N = 33) Number (%) of subjects with event
AE≤Grade 2≥Grade 3
Injection site reactiona28 (84.4)0 (0)
Chills19 (57.6)0 (0)
Pyrexia15 (45.5)0 (0)
Fatigue13 (39.4)0 (0)
Nausea11 (33.3)0 (0)
Decreased appetite8 (24.4)0 (0)
Influenza like illness8 (24.4)0 (0)
Vomiting7 (21.1)0 (0)
Abdominal pain4 (12.1)2 (6.1)
Peripheral edema4 (12.1)1 (3.0)
Urinary tract infection3 (9.1)2 (6.1)
Anemia2 (6.1)2 (6.1)
Pain4 (12.1)0 (0)
Dehydration4 (12.1)0 (0)
Dyspnea3 (9.1)1 (3.0)
Hypomagnesaemia4 (12.1)0 (0)
  • a“Injection site reaction” includes MedDRA terms injection site nodule, injection site pruritus, injection site reaction, injection site erythema, injection site irritation, and injection site pain.